The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September.
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
Nick Paul Taylor